- Home
- DXCM vs BNTX Comparison
DXCM vs BNTX Comparison
Compare DXCM & BNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXCM
- BNTX
- Stock Information
- Founded
- DXCM 1999
- BNTX 2008
- Country
- DXCM United States
- BNTX Germany
- Employees
- DXCM N/A
- BNTX N/A
- Industry
- DXCM Medical/Dental Instruments
- BNTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DXCM Health Care
- BNTX Health Care
- Exchange
- DXCM Nasdaq
- BNTX Nasdaq
- Market Cap
- DXCM 34.1B
- BNTX 25.0B
- IPO Year
- DXCM 2005
- BNTX 2019
- Fundamental
- Price
- DXCM $83.95
- BNTX $109.95
- Analyst Decision
- DXCM Strong Buy
- BNTX Strong Buy
- Analyst Count
- DXCM 20
- BNTX 18
- Target Price
- DXCM $98.50
- BNTX $141.55
- AVG Volume (30 Days)
- DXCM 3.7M
- BNTX 771.1K
- Earning Date
- DXCM 07-30-2025
- BNTX 08-04-2025
- Dividend Yield
- DXCM N/A
- BNTX N/A
- EPS Growth
- DXCM N/A
- BNTX N/A
- EPS
- DXCM 1.33
- BNTX N/A
- Revenue
- DXCM $4,148,000,000.00
- BNTX $2,968,331,171.00
- Revenue This Year
- DXCM $16.74
- BNTX N/A
- Revenue Next Year
- DXCM $15.29
- BNTX $10.68
- P/E Ratio
- DXCM $62.25
- BNTX N/A
- Revenue Growth
- DXCM 9.11
- BNTX 0.61
- 52 Week Low
- DXCM $57.52
- BNTX $76.53
- 52 Week High
- DXCM $117.19
- BNTX $131.49
- Technical
- Relative Strength Index (RSI)
- DXCM 48.21
- BNTX 57.74
- Support Level
- DXCM $82.75
- BNTX $105.35
- Resistance Level
- DXCM $87.49
- BNTX $109.68
- Average True Range (ATR)
- DXCM 2.64
- BNTX 2.56
- MACD
- DXCM -0.16
- BNTX 0.05
- Stochastic Oscillator
- DXCM 48.72
- BNTX 87.00
About DXCM DexCom Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
About BNTX BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.